Ryan Brown has stepped down from his role as Sarepta Therapeutics’ executive vice president and chief general counsel, effective November 26, according to an SEC filing from the company.
Sarepta states in the Form 8K that Cristin Rothfuss, the company’s senior vice president and deputy general counsel, succeeds Brown as executive vice president and general counsel. According to the filing, Brown will continue as a non-executive employee of the company until around May 9, 2025 to support the transition.
Requests for comment from the company and Brown were not returned immediately.
Brown joined Sarepta in February 2018 as vice president, global chief compliance officer (CCO) and regulatory counsel, becoming general counsel in February 2021. As chief general counsel, he was responsible for the company’s global legal and compliance functions.
According to his LinkedIn profile, before joining Sarepta, Brown was vice president and CCO at ACADIA Pharmaceuticals. Before that, he was vice president and CCO at Allergan. He was previously an attorney with Jones Day where he practiced in the corporate criminal investigations and general litigation fields.
Rothfuss’ LinkedIn profile states that she joined Sarepta in 2018 as executive director for corporate transactions. She was previously executive director for institutional initiatives in the office of technology development at Harvard University. She had also been director of technology transactions at Harvard. Rothfuss had earlier been an attorney with law firms Bernstein, Cushner & Kimmell and Ivey, Barnum & O’Mara.
Ben Maiden
Ben Maiden is the editor-at-large of Governance Intelligence, an IR Media publication, having joined the company in December 2016. He is based in New York. Ben was previously managing editor of Compliance Reporter, covering regulatory and compliance...
